This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
Accept
Decline
MENU
CLOSE
language
Powerful, accessible cell therapies for patients with cancer.

We develop innovative, highly effective cell therapies for cancer that are broadly accessible for patients.
FIND US
Acepodia USA
1600 Harbor Bay Parkway, Suite 140,
Alameda, CA 94502,
USA
Acepodia Taiwan
12F., No. 508, Sec. 7, Zhongxiao E. Rd.,
Nangang Dist., Taipei City 115011,
Taiwan (R.O.C.).
CONTACT US
Tel: +1 (415) 366 7822 Email: info@acepodiabio.com
FOLLOW US
Copyright © 2020 Acepodia Inc.
Privacy Policy Terms of use

Investors

CONTACT

If you have any questions or suggestions about investor services, please email   ir@acepodiabio.com
We sincerely thank you for your support to Acepodia.

Stock Transfer Agent
Taishin Securities Co., Ltd., Stock Transfer Agency Department

Tel: (02) 2504-8125 ext. 9

Address: B1, No. 96, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City

Mailing Address:
P.O. Box 46-300, Taipei, Taiwan 104946

Website: 
https://www.tssco.com.tw/stocktransfer

 

Audit Committee

1. Audit Committee
 
The Company established its Audit Committee on April 26, 2023, composed of all independent directors.
The Committee's responsibilities are as follows:
(a) Formulating or amending the internal control system;
(b) Assessing the effectiveness of the internal control system;
(c) Formulating or amending procedures for significant financial and business activities, including acquisition or 
      disposal of assets, derivatives trading, lending of funds to others, and endorsements or guarantees for others;
(d) Matters involving a director's personal conflict of interest;
(e) Significant asset or derivatives transactions;
(f) Significant fund lending, endorsements, or guarantees;
(g) Fundraising, issuance, or private placement of shares or equity-linked securities;
(h) Appointment, dismissal, or remuneration of the certifying accountant;
(i) Appointment or dismissal of financial, accounting, or internal audit supervisors;
(j) Approval of the annual financial report and the Q2 financial report subject to CPA audit and certification; and
(k) Other material matters as determined by the board of directors or required by any competent authority or listing
      regulations.
 
2. 2nd Audit Committee — Term: February 6, 2026 to February 5, 2029
 
Member Qualifications & Experience
Angus Tsai (Convener)
  • Education: M.S. in Accounting, Chung Yuan Christian University
  • Past Experience: Deputy Section Chief, Taiwan OTC Center; Associate Researcher, Taiwan Securities and Futures Market Development Foundation; Assistant Manager of Financial Planning, Eastern Broadcasting Co.; Auditor, KPMG; Lecturer, National Open University; Compensation Committee Member, Cayman Islands-registered Chunji Holdings
  • Current Positions: CPA (Sustainability & IPO Advisory Division), Deloitte; Legal Entity Director Representative, Tianyu Industrial Co., Ltd.; Independent Director, Tiange International Co., Ltd.
Jo Shen
  • Education: Ph.D. in Physical Chemistry, Lehigh University; M.S. in Inorganic Chemistry, University of Iowa
  • Past Experience: Co-founder, Director, President & CEO, ScinoPharm Taiwan; Founder, Biotech Industry Deep Cultivation Academy; President, ScinoPharm USA; VP, Syntex Pharmaceuticals (USA); Wafer Fab Manager, Monsanto Chemical (USA)
  • Current Positions: Founding Partner, Vivo Capital; Director, Handa Biopharma; Director, Taiwan Liposome Company; Director, Anhong Biomedical; Director, Shenghua Biotech; Legal Entity Director Representative, Dingsheng Biotech; Independent Director, Shuntian Pharmaceutical Biotech; Independent Director, Zhongen Biomedical Technology; Vice Chairman, Taiwan Bioindustry Organization; Advisory Committee Member, National Health Research Institutes; Academic Advisory Committee Member, Academia Sinica Biomedical Translation Research Center; Enterprise Advisory Committee Member, College of Commerce, National Chengchi University
Kunming Rao
  • Education: M.S. in Clinical Medicine, Chang Gung University
  • Past Experience: Research, Cancer Molecular & Cell Biology Dept., MD Anderson Cancer Center, Texas; Chief of Hematology & Oncology, Kaohsiung Chang Gung Memorial Hospital; Director, Kaohsiung Chang Gung Cancer Prevention & Treatment Center; Director, Taiwan Society of Cancer Medicine; Supervisor, Taiwan Breast Oncology Society; Standing Supervisor, Taiwan Hospice & Palliative Medicine Society
  • Current Positions: Deputy Director of Internal Medicine, E-Da Cancer Hospital; Supervisor, Taiwan Breast Oncology Society; Standing Supervisor, Taiwan Hospice & Palliative Medicine Society; Director, Taiwan Gastric Cancer Society; Adjunct Professor, School of Medicine, I-Shou University
Sung-Hsin Kuo
  • Education: Ph.D. in Clinical Medicine, College of Medicine, National Taiwan University
  • Past Experience: Attending Physician, Dept. of Oncology, NTU Hospital; Associate Professor, Graduate Institute of Oncology, NTU College of Medicine; Chief, Dept. of Oncology, NTU Hospital Yunlin Branch; Clinical Associate Professor, Dept. of Internal Medicine, NTU College of Medicine; Researcher, Institut Curie, France; Resident/Researcher, Dept. of Oncology, NTU Hospital; Resident Physician, Dept. of Internal Medicine, NTU Hospital
  • Current Positions: Professor, Graduate Institute of Oncology, NTU College of Medicine; Chief, Division of Radiation Oncology, Dept. of Oncology, NTU Hospital
  
3. Audit Committee Attendance
 
     As of August 2026, the Committee has held  5  meetings (A). Attendance is as follows:
Member Actual Attendance (B) Attended by Proxy Attendance Rate (B/A)
Angus Tsai 5 0 100%
Jo Shen 5 0 100%
Kunming Rao 5 0 100%
Sung-Hsin Kuo 5 0 100%